- Home
- DUOT vs ZNTL Comparison
DUOT vs ZNTL Comparison
Compare DUOT & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DUOT
- ZNTL
- Stock Information
- Founded
- DUOT 1990
- ZNTL 2014
- Country
- DUOT United States
- ZNTL United States
- Employees
- DUOT N/A
- ZNTL N/A
- Industry
- DUOT Computer Software: Prepackaged Software
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- DUOT Technology
- ZNTL Health Care
- Exchange
- DUOT Nasdaq
- ZNTL Nasdaq
- Market Cap
- DUOT 101.7M
- ZNTL 105.8M
- IPO Year
- DUOT N/A
- ZNTL 2020
- Fundamental
- Price
- DUOT $6.35
- ZNTL $1.44
- Analyst Decision
- DUOT Strong Buy
- ZNTL Buy
- Analyst Count
- DUOT 2
- ZNTL 7
- Target Price
- DUOT $12.50
- ZNTL $8.46
- AVG Volume (30 Days)
- DUOT 314.8K
- ZNTL 570.1K
- Earning Date
- DUOT 08-14-2025
- ZNTL 08-06-2025
- Dividend Yield
- DUOT N/A
- ZNTL N/A
- EPS Growth
- DUOT N/A
- ZNTL N/A
- EPS
- DUOT N/A
- ZNTL N/A
- Revenue
- DUOT $11,162,390.00
- ZNTL $26,865,000.00
- Revenue This Year
- DUOT $294.36
- ZNTL N/A
- Revenue Next Year
- DUOT $43.87
- ZNTL N/A
- P/E Ratio
- DUOT N/A
- ZNTL N/A
- Revenue Growth
- DUOT 89.27
- ZNTL N/A
- 52 Week Low
- DUOT $2.22
- ZNTL $1.01
- 52 Week High
- DUOT $9.27
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- DUOT 35.63
- ZNTL 55.02
- Support Level
- DUOT $6.31
- ZNTL $1.35
- Resistance Level
- DUOT $7.08
- ZNTL $1.45
- Average True Range (ATR)
- DUOT 0.44
- ZNTL 0.08
- MACD
- DUOT -0.14
- ZNTL 0.00
- Stochastic Oscillator
- DUOT 2.38
- ZNTL 54.19
About DUOT Duos Technologies Group Inc.
Duos Technologies Group Inc operating under its brand name duostech, designs, develops, deploys and operates intelligent technology solutions supporting rail, logistics and intermodal businesses that streamline operations, improve safety and reduce costs. The company's main offering, the Railcar Inspection Portal (RIP), provides both freight and transit railroad customers and select government agencies the ability to conduct fully automated railcar inspections of trains that are moving at full speed. It has also developed the Automated Logistics Information System (ALIS) which automates gatehouse operations where transport trucks enter and exit large logistics and intermodal facilities. Its segments are Rail, Commercial, Governments, Banking and AI.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.